<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jesse Coutin on Medium]]></title>
        <description><![CDATA[Stories by Jesse Coutin on Medium]]></description>
        <link>https://medium.com/@jessecoutin?source=rss-a7ceb4114e6f------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*aRnoLLOIpCLnogPoSCliIA.png</url>
            <title>Stories by Jesse Coutin on Medium</title>
            <link>https://medium.com/@jessecoutin?source=rss-a7ceb4114e6f------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 20:13:21 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@jessecoutin/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[NAD+ Supplements Appear Over-Hyped for Anti-Aging After Evaluating Niacin]]></title>
            <link>https://medium.com/@jessecoutin/nad-supplements-appear-over-hyped-for-anti-aging-after-evaluating-niacin-fad25cbcf4e7?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/fad25cbcf4e7</guid>
            <category><![CDATA[supplements]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[nmn-supplement]]></category>
            <category><![CDATA[niacin]]></category>
            <category><![CDATA[nad]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Thu, 17 Feb 2022 04:31:56 GMT</pubDate>
            <atom:updated>2022-02-17T23:52:48.001Z</atom:updated>
            <content:encoded><![CDATA[<h4>More Research is Needed to Backup Claims</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/414/1*YUZuWfZqWmdKd5ESKX2NAQ.jpeg" /></figure><h4>Recent NAD+ supplements</h4><p>Nicotinamide Mononucleotide (NMN), Nicotinamide Riboside (NR), and other relatively new NAD+ precursor supplements have risen in popularity in recent years due to a marketing and media blitz by longevity supplement companies and their affiliates. These supplements have been lauded for a range of anti-aging effects, but at this point, these have been almost exclusively seen in mice. Modest improvements in health and lifespan have been demonstrated in mice, yet it is unknown whether these benefits will translate to humans[1]. Purported benefits (in aged mice) of NAD+ precursor supplements include increased performance during endurance exercise[2], better vascular functioning and vascular regeneration[2], some rejuvenation of aged stem cells[3,4], improved mitochondrial function[4,5], rescued female fertility<a href="https://www.zotero.org/google-docs/?uBPR8Z">[6]</a>, improved metabolism[5], decreased age-associated inflammation[7], and improved DNA repair[5]. The way these supplements are thought to cause these benefits is by raising levels of NAD+, a crucial molecule in cellular metabolism and respiration, levels of which fall naturally with age[8]. Raising NAD+ (NAD+ repletion) is also known to activate sirtuins, which stabilize telomeres[9] and promote healthy aging by signaling nutrient scarcity and catabolism[10].</p><h4>Niacin, an older NAD+ supplement</h4><p>There is, however, little that is revolutionary about these new supplements (NMN or NR). While they may be “NAD+ boosters,” substances which effectively/efficiently raise NAD+ levels, they are just the new kid on the block. They are derivatives of Niacin, also known as vitamin B3, a century-old and inexpensive NAD precursor supplement. A<a href="https://pubmed.ncbi.nlm.nih.gov/32386566/"> recent study</a> showed that niacin raises NAD+ levels in healthy humans and in those with mitochondrial myopathy, and confers several health benefits (improved strength and muscle mass, and reduced adiposity). Thus, niacin demonstrably raises NAD+ levels in humans[11], and has similar beneficial effects[11,12], in addition to being established as an effective LDL (“bad”) cholesterol-lowering medication[13]. Although there are common Niacin side-effects, such as flushing, bloating, and tingling, these are harmless and tend to go away with continued use[11,14,15]. More concerning are the less common, but more serious side-effects of Niacin, such as liver toxicity or damage, which can occur at very high dosages of the sustained release tablets, but are not as common with the regular or extended-release supplements, especially at lower dosages[16]. Additional uncommon side-effects, i.e. increased risk of diabetes, excess infections, and bleeding, increase moderately in those taking niacin with cardiovascular disease[17]. Still, it is worthwhile to consider niacin when attempting to gauge whether NAD supplements are effective for treating aging, especially given the aforementioned finding that niacin raises NAD levels in humans[11], and the fact niacin has been used for lowering cholesterol since the 1950s[13].</p><h4>Evidence that niacin improves lifespan or healthspan?</h4><p>If NAD+ supplementation is effective at ameliorating the effects of aging and lowering mortality risks, one would have expected to see this in data from studies on niacin administration over its many decades of use. For example, Metformin, an old medication originally and primarily prescribed for diabetes, but now popular in the longevity community for aging, is significantly associated with 15% greater median lifespan in diabetics than in non-diabetics not taking metformin[18]. This, by itself, is compelling evidence for a potential general use-case for metformin for aging. However, there are no studies that show any similar effect for niacin. In fact, in those with cardiovascular disease, no reduction in all-cause mortality or cardiovascular-related mortality has been demonstrated after an analysis of many studies on niacin supplementation at a wide range of dosages (500mg per day to 4,000mg per day)[19,20].</p><h4>Conclusion</h4><p>An evaluation of niacin leads one to question whether all the hype surrounding NAD+ supplementation is warranted. Although niacin can be effective at raising NAD+ levels, and may confer some physiological benefits, there is, as of yet, no evidence that it effectively reduces mortality or improves health. Therefore, while NAD+ supplements may have some benefits for healthy aging and deserve further study, at present, in light of the paucity of evidence for this in niacin, this appears overstated. Currently, there is no evidence that in humans NAD+ supplements can effectively reverse or treat aging, and they may not be the fountain of youth that one might have been led to believe by media-sources. More research is needed, and the onus is still on the companies selling these supplements and making these claims to provide clinical trial evidence of their purported anti-aging benefits in humans.</p><h4>Literature:</h4><p>1. Yoshino, J., Baur, J. A., &amp; Imai, S. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. <em>Cell Metabolism</em>, <em>27</em>(3), 513–528. <a href="https://doi.org/10.1016/j.cmet.2017.11.002">https://doi.org/10.1016/j.cmet.2017.11.002</a></p><p>2. Tarantini, S., Valcarcel-Ares, M. N., Toth, P., Yabluchanskiy, A., Tucsek, Z., Kiss, T., Hertelendy, P., Kinter, M., Ballabh, P., Süle, Z., Farkas, E., Baur, J. A., Sinclair, D. A., Csiszar, A., &amp; Ungvari, Z. (2019). Nicotinamide mononucleotide (NMN) supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses and improves cognitive function in aged mice. <em>Redox Biology</em>, <em>24</em>, 101192. <a href="https://doi.org/10.1016/j.redox.2019.101192">https://doi.org/10.1016/j.redox.2019.101192</a></p><p>3. Igarashi, M., Miura, M., Williams, E., Jaksch, F., Kadowaki, T., Yamauchi, T., &amp; Guarente, L. (2019). NAD+ supplementation rejuvenates aged gut adult stem cells. <em>Aging Cell</em>, <em>18</em>(3), e12935. <a href="https://doi.org/10.1111/acel.12935">https://doi.org/10.1111/acel.12935</a></p><p>4. Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., Schoonjans, K., Menzies, K. J., &amp; Auwerx, J. (2016). NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. <em>Science</em>, <em>352</em>(6292), 1436–1443. <a href="https://doi.org/10.1126/science.aaf2693">https://doi.org/10.1126/science.aaf2693</a></p><p>5. Nadeeshani, H., Li, J., Ying, T., Zhang, B., &amp; Lu, J. (2021). Nicotinamide mononucleotide (NMN) as an anti-aging health product — Promises and safety concerns. <em>Journal of Advanced Research</em>. <a href="https://doi.org/10.1016/j.jare.2021.08.003">https://doi.org/10.1016/j.jare.2021.08.003</a></p><p>6. Bertoldo, M. J., Listijono, D. R., Ho, W.-H. J., Riepsamen, A. H., Goss, D. M., Richani, D., Jin, X. L., Mahbub, S., Campbell, J. M., Habibalahi, A., Loh, W.-G. N., Youngson, N. A., Maniam, J., Wong, A. S. A., Selesniemi, K., Bustamante, S., Li, C., Zhao, Y., Marinova, M. B., … Wu, L. E. (2020). NAD+ Repletion Rescues Female Fertility during Reproductive Aging. <em>Cell Reports</em>, <em>30</em>(6), 1670–1681.e7. <a href="https://doi.org/10.1016/j.celrep.2020.01.058">https://doi.org/10.1016/j.celrep.2020.01.058</a></p><p>7. Mills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., Yoshino, J., &amp; Imai, S. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. <em>Cell Metabolism</em>, <em>24</em>(6), 795–806. <a href="https://doi.org/10.1016/j.cmet.2016.09.013">https://doi.org/10.1016/j.cmet.2016.09.013</a></p><p>8. Schultz, M. B., &amp; Sinclair, D. A. (2016). Why NAD+ Declines during Aging: It’s Destroyed. <em>Cell Metabolism</em>, <em>23</em>(6), 965–966. <a href="https://doi.org/10.1016/j.cmet.2016.05.022">https://doi.org/10.1016/j.cmet.2016.05.022</a></p><p>9. Amano, H., Chaudhury, A., Rodriguez-Aguayo, C., Lu, L., Akhanov, V., Catic, A., Popov, Y. V., Verdin, E., Johnson, H., Stossi, F., Sinclair, D. A., Nakamaru-Ogiso, E., Lopez-Berestein, G., Chang, J. T., Neilson, J. R., Meeker, A., Finegold, M., Baur, J. A., &amp; Sahin, E. (2019). Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. <em>Cell Metabolism</em>, <em>29</em>(6), 1274–1290.e9. <a href="https://doi.org/10.1016/j.cmet.2019.03.001">https://doi.org/10.1016/j.cmet.2019.03.001</a></p><p>10. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., &amp; Kroemer, G. (2013). The Hallmarks of Aging. <em>Cell</em>, <em>153</em>(6), 1194–1217. <a href="https://doi.org/10.1016/j.cell.2013.05.039">https://doi.org/10.1016/j.cell.2013.05.039</a></p><p>11. Pirinen, E., Auranen, M., Khan, N. A., Brilhante, V., Urho, N., Pessia, A., Hakkarainen, A., Kuula, J., Heinonen, U., Schmidt, M. S., Haimilahti, K., Piirilä, P., Lundbom, N., Taskinen, M.-R., Brenner, C., Velagapudi, V., Pietiläinen, K. H., &amp; Suomalainen, A. (2020). Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. <em>Cell Metabolism</em>, <em>31</em>(6), 1078–1090.e5. <a href="https://doi.org/10.1016/j.cmet.2020.04.008">https://doi.org/10.1016/j.cmet.2020.04.008</a></p><p>12. Rajman, L., Chwalek, K., &amp; Sinclair, D. A. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. <em>Cell Metabolism</em>, <em>27</em>(3), 529–547. <a href="https://doi.org/10.1016/j.cmet.2018.02.011">https://doi.org/10.1016/j.cmet.2018.02.011</a></p><p>13. <a href="https://www.aafp.org/afp/2004/0901/p956.html">Over-the-Counter Niacin Preparations for Dyslipidemia</a>. (2004). <em>American Family Physician</em>, <em>70</em>(5), 956.</p><p>14. Kamanna, V. S., Ganji, S. H., &amp; Kashyap, M. L. (2009). The mechanism and mitigation of niacin-induced flushing. <em>International Journal of Clinical Practice</em>, <em>63</em>(9), 1369–1377. <a href="https://doi.org/10.1111/j.1742-1241.2009.02099.x">https://doi.org/10.1111/j.1742-1241.2009.02099.x</a></p><p>15. Stern, R. H., Spence, J. D., Freeman, D. J., &amp; Parbtani, A. (1991). Tolerance to nicotinic acid flushing. <em>Clinical Pharmacology and Therapeutics</em>, <em>50</em>(1), 66–70. <a href="https://doi.org/10.1038/clpt.1991.104">https://doi.org/10.1038/clpt.1991.104</a></p><p>16. Niacin. (2012). In <em>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</em>. National Institute of Diabetes and Digestive and Kidney Diseases. <a href="http://www.ncbi.nlm.nih.gov/books/NBK548176/">http://www.ncbi.nlm.nih.gov/books/NBK548176/</a></p><p>17. Haynes, R., Valdes-Marquez, E., Hopewell, J. C., Chen, F., Li, J., Parish, S., Landray, M. J., Armitage, J., HPS2-THRIVE Collaborative Group, HPS2-THRIVE Writing Committee members, &amp; HPS2-THRIVE Steering Committee members. (2019). Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. <em>Clinical Therapeutics</em>, <em>41</em>(9), 1767–1777. <a href="https://doi.org/10.1016/j.clinthera.2019.06.012">https://doi.org/10.1016/j.clinthera.2019.06.012</a></p><p>18. Bannister, C. A., Holden, S. E., Jenkins-Jones, S., Morgan, C. Ll., Halcox, J. P., Schernthaner, G., Mukherjee, J., &amp; Currie, C. J. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. <em>Diabetes, Obesity and Metabolism</em>, <em>16</em>(11), 1165–1173. <a href="https://doi.org/10.1111/dom.12354">https://doi.org/10.1111/dom.12354</a></p><p>19. Shaughnessy, A. F. (2017). <a href="https://www.aafp.org/afp/2017/0715/p129.html#:~:text=Although%20niacin%20can%20increase%20HDL,or%20the%20need%20for%20revascularization.">Niacin Does Not Decrease Mortality in Patients with Coronary Artery Disease or Low HDL</a>. <em>American Family Physician</em>, <em>96</em>(2), 129–129.</p><p>20. Schandelmaier, S., Briel, M., Saccilotto, R., Olu, K. K., Arpagaus, A., Hemkens, L. G., &amp; Nordmann, A. J. (2017). Niacin for primary and secondary prevention of cardiovascular events. <em>The Cochrane Database of Systematic Reviews</em>, <em>2017</em>(6), CD009744. <a href="https://doi.org/10.1002/14651858.CD009744.pub2">https://doi.org/10.1002/14651858.CD009744.pub2</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fad25cbcf4e7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Metformin May Be the Gateway to Curing Aging]]></title>
            <link>https://medium.com/@jessecoutin/metformin-may-be-the-gateway-to-curing-aging-a5d35ab3c767?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/a5d35ab3c767</guid>
            <category><![CDATA[longevity]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[metformin]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Sat, 15 Aug 2020 00:58:21 GMT</pubDate>
            <atom:updated>2020-08-15T00:58:21.804Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*w__rVfQ8VY22CBgJqcH9NA.jpeg" /></figure><h3>A Review: Metformin — A Promising Gerotherapeutic for Clinical Trials</h3><p>Researchers at Albert Einstein College of Medicine and the National Institute of Health (NIH) have put together an intriguing new <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347426/">review</a> in the journal Cell Metabolism on the benefits of the drug metformin, specifically in terms of metformin’s ability to diminish the hallmarks of aging [1]. I’ll get to that in a bit. First, here is some background on metformin, and why it is the subject of an extensive collaborative review.</p><p><strong>Metformin extends health-span and life-span according to multiple studies</strong></p><p>Metformin, is a biguanide, a type of glucose lowering medication, and has been used as a first-line treatment for Diabetes Type 2 for over 60 years. Currently it is only available with a doctor’s prescription. However, research is showing that perhaps metformin should be repurposed to treat aging. Metformin has been of particular interest in aging research because multiple study types, from epidemiological studies to clinical studies to association studies, have found that metformin decreases incidence of age-related diseases and decreases mortality [1]. It is particularly telling that diabetics on metformin lived 15% longer than matched non-diabetics not taking metformin according to a <a href="https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.12354">large retrospective observational study</a> [2]. The soon to be launched <a href="https://www.afar.org/tame-trial">TAME</a> trial (Targeting Aging by Metformin), which has now received sufficient funding coordinated by the American Federation of Aging Research (AFAR), may be able to confirm metformin’s efficacy in slowing aging.</p><p><strong>Metformin has a high safety profile</strong></p><p>Metformin has been thoroughly studied and has been found to have a high safety profile, usually having only minor short-lasting side-effects, such as gastrointestinal discomfort. In long-term administration it can cause vitamin B12 levels to fall, requiring B12 supplementation. Metformin is also known to raise lactate levels to within the normal limits, but this can cause a condition called Metformin Associated Lactic Acidosis (MALA) in patients who have a pre-existing server liver, kidney, or heart condition [1].</p><p><strong>Every hallmark of aging is attenuated by Metformin</strong></p><p>This <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347426/">review</a> used data from studies on model organisms and human cell lines, as well as data from observational studies of people taking metformin, and determined that metformin diminishes each of the <a href="https://medium.com/@jessecoutin/what-causes-aging-how-much-have-we-learned-in-recent-years-93b85e6a594a">nine hallmarks of aging</a>, either directly or by a downstream effect:</p><p><strong>1) Deregulated nutrient signaling:</strong> While metformin is best understood as an AMPK activator, thereby directly targeting one of the nutrient signaling pathways that is deregulated with aging, it has recently been discovered to target all four nutrient signaling pathways. This suggests that it may increase lifespan by mimicking dietary restriction. By a series of complex mechanisms, metformin downregulates mTORC1 and Insulin/IGF1 Signaling (IIS), two anabolic (tissue building) nutrient sensing pathways which sense high levels of nutrients. Conversely, metformin upregulates AMPK and SIRT1, two catabolic (tissue break-down) nutrient sensing pathways which sense low levels of nutrients. Downregulation of the mTOR and IIS pathways, and upregulation of the AMPK and sirtuin pathways have been shown to increase lifespan.</p><p><strong>2) Altered intercellular communication:</strong> Inflammation increases with age, and metabolism becomes less efficient, however metformin improves insulin metabolism and sensitivity which may decrease systemic inflammation by decreasing body-weight. Metformin also reduces inflammation by reducing levels of pro-inflammatory cytokines, a type of signaling molecule which promotes inflammation, and by inhibiting the NF-kB pathway, a protein complex which has been implicated in upregulating inflammation. There is also evidence that metformin causes changes in the composition of the gut microbiome, which may also be responsible for metformin’s benefits in regard to metabolism and inflammation. Thus, metformin may directly counteract inflammaging, an inflammation phenotype associated with altered intercellular communication with age.</p><p><strong>3) Genomic instability:</strong> There is evidence that metformin reduces oxidative stress, stimulates a DNA damage response, and stimulates DNA repair. Overall there is no consensus as to how metformin does this, so more research is needed to determine the exact mechanisms, and to determine to what extent metformin prevents genomic instability with increased age.</p><p><strong>4) Loss of proteostasis:</strong> In mouse models with disease or protein misfolding, metformin beneficially upregulated autophagy (the process by which the body destroys its own proteins or cells), and metformin has also been shown to reverse the misfolding of certain proteins. This suggests that metformin may slow or prevent the protein misfolding that occurs with aging.</p><p><strong>5) Mitochondrial dysfunction:</strong> Mitochondria decrease in function with increased age, however metformin appears to reverse this process. Metformin does this in two ways: First, it inhibits mitochondrial complex 1 in the cell, which reduces inflammation and reactive oxygen species (ROS). Second, metformin increases mitochondrial biogenesis (the process by which mitochondria grow and reproduce), by increasing the activity of PGC-1α (a protein which transcriptionally regulates mitochondrial biogenesis) in the liver and skeletal muscle.</p><p><strong>6) Stem Cell Exhaustion:</strong> Metformin may be able to delay stem cell aging by rejuvenating stem cells in multiple organs through several complex mechanisms. More research is needed, but there is evidence that metformin prevents DNA damage to stem cells and maintains or expands stem cell populations.</p><p><strong>7) Epigenetic Alterations:</strong> Epigenetics, modifications that affect gene activity without changing the DNA, are altered with aging in a variety of ways. Metformin beneficially modifies some of these epigenetic changes, such as histone modifications, DNA methylation, and miRNAs, but only does this at doses higher than clinical doses, or when used in combination with other drug therapies.</p><p><strong>8) Telomere Attrition:</strong> Telomeres, the protective complexes at the ends of DNA chromosomes, progressively shorten throughout life, which eventually leads to cellular senescence, triggers inflammation, and can cause mitochondrial dysfunction. This <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347426/">review</a> cites several studies in which metformin prevented telomere shortening or reduced telomere shortening.</p><p><strong>9) Cellular Senescence:</strong> Cellular senescence, which occurs when a cell loses its function and stops diving, is thought to be one of the key drivers of aging. Metformin delays senescence by an unknown mechanism, and inhibits senescence-associated secretory phenotype (SASP), by inhibiting the inflammatory cytokines secreted by senescent cells.</p><p><strong>Abstract</strong></p><blockquote>Biological aging involves an interplay of conserved and targetable molecular mechanisms, summarized as the hallmarks of aging. Metformin, a biguanide that combats age-related disorders and improves health span, is the first drug to be tested for its age-targeting effects in the large clinical trial — <a href="https://www.afar.org/tame-trial">TAME</a> (targeting aging by metformin). This <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347426/">review</a> focuses on metformin’s mechanisms in attenuating hallmarks of aging and their interconnectivity, by improving nutrient sensing, enhancing autophagy and intercellular communication, protecting against macromolecular damage, delaying stem cell aging, modulating mitochondrial function, regulating transcription, and lowering telomere attrition and senescence. These characteristics make metformin an attractive gerotherapeutic to translate to human trials.</blockquote><p><strong>Conclusion</strong></p><p>It is evident that metformin positively affects all nine hallmarks of aging, but it is also clear that much more research is needed. Furthermore, metformin is not a panacea for the effects of aging, and since it has been in use for such a long time, no one expects it to be a cure. The research described in this <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347426/">review</a> provides hope that the <a href="https://www.afar.org/tame-trial">TAME</a> trial will be able to further elucidate the cellular mechanisms of metformin’s activity in regards to each of the hallmarks or aging, and will also provide more evidence of modest improvements in health and lifespan. Additionally, positive results from the trial in terms of decreased incidence of age-associated disease indicators and decreased mortality would certainly give researchers in the field of developing aging-interventions more confidence. One cannot emphasize the importance of the <a href="https://www.afar.org/tame-trial">TAME</a> trial enough, since a successful <a href="https://www.afar.org/tame-trial">TAME</a> trial will pave the way for FDA approval of aging as a target for drug R&amp;D. This will likely make investment and pharmaceutical companies more willing to pursue development of other more effective therapies for the indication of aging. Thus, metformin may be the gateway to the cure.</p><p><strong>Literature</strong></p><p>[1] Kulkarni, A. S., Gubbi, S., &amp; Barzilai, N. (2020). Benefits of Metformin in Attenuating the Hallmarks of Aging. <em>Cell metabolism</em>, <em>32</em>(1), 15–30.</p><p>[2] Bannister, C.A., Holden, S.E., Jenkins‐Jones, S., Morgan, C.L., Halcox, J.P., Schernthaner, G., Mukherjee, J. and Currie, C.J. (2014), Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls. Diabetes Obes Metab, 16: 1165–1173.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a5d35ab3c767" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Aging Research; Where is the Funding?]]></title>
            <link>https://medium.com/@jessecoutin/aging-research-where-is-the-funding-4c724726dee5?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/4c724726dee5</guid>
            <category><![CDATA[research]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[funding]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[advocacy]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Fri, 14 Aug 2020 01:36:32 GMT</pubDate>
            <atom:updated>2021-09-03T21:17:24.934Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*2Isjfcb6GmsmsqSs2GZoiw.jpeg" /><figcaption>Photo by Author</figcaption></figure><h4>There is insufficient Federal funding for aging research</h4><p>Federal funding for aging research comes from the National Institute on Aging (NIA). The NIA is a division of the National Institute of Health (NIH), which is the largest biomedical research agency on Earth, and the medical research arm of the U.S. department of Health and Human Services (HHS) [1]. The NIA is requesting $3.2 billion for fiscal year (FY) 2021, a <strong>decrease</strong> of about 10% from FY 2020. The NIA will only allocate 10% of its budget, $322.6 million, to its Division of Aging Biology (DAB), which</p><blockquote>supports research to determine the basic biochemical and genetic mechanisms underlying the processes of aging at the cell, tissue, and organ levels and the ways these are communicated among cells and tissues of the body</blockquote><p>[2]. The research done by the DAB is arguably closest to what we mean in regards to research on the biology of aging, yet it receives only 10% of the NIA budget.</p><blockquote>Aging research is far too valuable to only account for less than a quarter of a percent of discretionary funding.</blockquote><p>The NIA’s requested budget for FY 2021 is only 0.24% of the United States proposed discretionary budget for 2021, and the NIA’s DAB budget is only 0.024% of the United States discretionary budget [3]. Aging research is far too valuable to only account for less than a quarter of a percent of discretionary funding. And research on the biology of aging through the DAB, which includes research on treating aging with therapies such as senolytics, is receiving a negligible amount of funding given the enormous potential of such therapies to slow or reverse aging.</p><h4><strong>How much funding is there from philanthropists and non-profits?</strong></h4><p>It is hard to gauge the amount of funding from extra-governmental sources when it comes to aging research. There are several non-government organizations and non-profits that fund aging research. Several notable ones are the Life Extension Advocacy Organization (LEAF), the Glenn Foundation for Medical Research, and the Scientifically Engineered Negligible Senescence (SENS) Research Foundation, and the Methuselah Foundation.</p><p>·<strong>The Clock Foundation, </strong>a non-profit organization founded by biostatician and UCLA professor Dr. Steve Horvath and bioengineer and UCLA alum Bobby Brooke, is dedicated to furthering the development and availability of biomarker testing, with an emphasis on epigenetic aging clocks, for use by researchers, physicians/clinics, and drug-development companies. They aim to reduce testing costs, perform mechanistic studies, and to develop more powerful biomarkers of health-span and life-span for humans, model organisms, and pets. Their team provides testing and analysis of several aging biomarkers, including epigenetic aging clocks, markers of immunosenescence, and markers of organ dysfunction, and partners with researchers to conduct proof-of-concept aging studies. They have plans to enable large-scale preclinical and clinical trial infrastructure in the U.S. and internationally for promising anti-aging treatments [4].</p><p>· <strong>The Glenn Foundation</strong>, a non-profit funded by philanthropist Paul F. Glenn, provides funding to its nine Glenn Centers for Aging Research, which exist at Stanford, the Buck Institute, MIT, Princeton, the Salk Institute, Albert Einstein College of Medicine, University of Michigan, Harvard, and the Mayo Clinic [5]. The Glenn Foundation also provides funding for the American Federation for Aging Research (AFAR) to coordinate funding and research grants [6], and with Bay Area Aging Meeting (BAAM) which organizes bi-annual networking meetings for researchers in the field of aging [7].</p><p>· <strong>LEAF</strong> is an advocacy and crowdfunding non-profit with the aim of “advocating and supporting the development of biotechnologies with the goal of ending age-related diseases.” The LEAF website, Lifespan.io features news on aging research, interviews with top scientists and advocates, information and videos highlighting the science of aging, the drug pipelines of promising companies in the field, and a Covid-19 roadmap, among many other resources for those interested in educating themselves or getting involved. Crowdfunding goes towards research projects sponsored by LEAF, and one can choose to donate to specific projects or to the LEAF organization [8].</p><p>· <strong>SENS Research Foundation</strong> is a non-profit that funds research on aging aimed at the development of “rejuvenation biotechnologies,” which it defines as technologies to “remove, repair, replace, or render harmless the cellular and molecular damage caused by the biological aging process” [9].</p><p>· <strong>The Methuselah Foundation </strong>is a non-profit biomedical charity that funds companies pursuing anti-aging therapies. Its goal is to “make 90 the new 50 by 2030” [10].</p><h4><strong>How much funding is there from venture capital?</strong></h4><p>Venture capital is also involved in researching and fighting aging. There are many companies researching and developing aging therapies, but again, it is difficult to determine the amount of money involved. A few notable companies in terms of their mission and total funding are Calico, Unity Biotechnology, and the Longevity Fund.</p><p>· Google’s <strong>Calico</strong>, California Life Company, is a R&amp;D company that has been stealthily researching the biology of aging with the goal of creating interventions [11]. Since its founding in 2013, 2.5 billion dollars have been invested in Calico through a joint venture between Google and AbbVie [12]. Calico is very secretive, so little is known about their research projects or drug pipeline [13].</p><p>· <strong>Unity Biotechnology</strong>, a start-up founded in 2009, is trying to cure age-related diseases by targeting the mechanisms of aging. Its focus is on senescent cells and it has received multi-hundred million dollar investments by Amazon CEO, Jeff Bezos’, and PayPal cofounder, Peter Thiel [14].</p><p>· <strong>The Longevity Fund </strong>is a venture capital company, founded in 2011, that invests in Seed and Series A companies developing drugs for aging and age-related diseases. According to its website, the companies it has invested in have collected greater than $500 million dollars in follow-on funding [15].</p><h4><strong>We need to advocate for more funding for research and development that targets aging.</strong></h4><p>Fighting aging needs to be made a top priority. Considering that aging and age-related illness are the leading causes of death and morbidity in the developed world [16], funding for aging research and potential aging therapies needs to be a platform-level issue that receives as much attention as defense budgets and health insurance. There is negligible funding from the U.S. government for aging research, so funding has had to come from other sources such as non-profits and the private sector. We need something similar to ‘Operation Warp Speed,’ the U.S. government’s $10 billion dollar effort to accelerate the development of vaccines for COVID-19.</p><p>Advocacy for aging research starts with us, at the individual level. We must make it a priority in our political lives. We can tell those we know via social media to raise awareness that aging is a potentially curable condition and that it is not being given enough attention. We can consider donating to aging advocacy organizations. We can start petitions for aging research to be better funded and more rigorously pursued. Aging research will continue to occur at institutions, companies, and universities at a somewhat sluggish pace unless we make our voices heard! It is clear that we need a grass-roots approach to advocate for accelerated research that will eventually lead to Fortune 500 companies, politicians, and others with financial or political power taking notice and taking action.</p><p>Find previous articles in this series here:</p><p><a href="https://medium.com/@jessecoutin/where-is-the-operation-warp-speed-for-aging-2e3b21c606f4">Where is the ‘Operation Warp Speed’ for Aging?</a></p><p><a href="https://medium.com/@jessecoutin/what-causes-aging-how-much-have-we-learned-in-recent-years-93b85e6a594a">What causes Aging? How Much Have we Learned in Recent Years?</a></p><p><a href="https://medium.com/@jessecoutin/recent-breakthroughs-in-research-give-hope-in-the-quest-to-cure-aging-cc34e26285a0">Recent Breakthroughs in Research Give Hope in the Quest to Cure Aging</a></p><h4>References:</h4><p>[1] About NIH. (n.d.). Retrieved July 20, 2020, from <a href="https://www.nih.gov/about-nih">https://www.nih.gov/about-nih</a></p><p>[2] Fiscal Year 2021 Budget. (n.d.). Retrieved July 20, 2020, from <a href="https://www.nia.nih.gov/about/budget/fiscal-year-2021-budget">https://www.nia.nih.gov/about/budget/fiscal-year-2021-budget</a></p><p>[3] United States, Office of Management and Budget. (2020). <em>A Budget for America’s Future</em>. Retrieved July 20, 2020, from <a href="https://whitehouse.gov/omb/budget/">https://whitehouse.gov/omb/budget/</a></p><p>[4] Clock Foundation. (2021, July 5). <em>About the Clock Foundation</em>. Retrieved September 3, 2021, from <a href="https://clockfoundation.org/about-the-clock-foundation/">https://clockfoundation.org/about-the-clock-foundation/</a></p><p>[5] Glenn Foundation for Medical Research. (2020). Retrieved July 21, 2020, from <a href="https://glennfoundation.org/">https://glennfoundation.org/</a></p><p>[6] AFAR | American Federation for Aging Research. (2020). Retrieved July 21, 2020, from <a href="https://www.afar.org/about-afar">https://www.afar.org/about-afar</a></p><p>[7] Bay Area Aging Meeting. (2020). Retrieved July 21, 2020, from <a href="https://agingmeeting.org/">https://agingmeeting.org/</a></p><p>[8] LEAF | Life Extension Advocacy Foundation. (2020). Retrieved July 21, 2020, from <a href="https://www.lifespan.io/">https://www.lifespan.io/</a></p><p>[9] SENS Research Foundation. (2020). Retrieved July 21, 2020, from <a href="https://www.sens.org/our-research/">https://www.sens.org/our-research/</a></p><p>[10] Springfield, VA, 22153United States. (2020). WHO WE ARE. Retrieved July 21, 2020, from <a href="https://www.mfoundation.org/who-we-are#about-us">https://www.mfoundation.org/who-we-are#about-us</a></p><p>[11] Calico. (2020). Retrieved July 21, 2020, from <a href="https://www.calicolabs.com/">https://www.calicolabs.com/</a></p><p>[12] Salinas, S., &amp; LaVito, A. (2018, June 26). Google sister company and drug giant chip in another $1 billion to cure age-related diseases. Retrieved July 21, 2020, from <a href="https://www.cnbc.com/2018/06/26/alphabet-backed-calico-and-abbvie-chip-in-1-billion-to-cure-aging.html">https://www.cnbc.com/2018/06/26/alphabet-backed-calico-and-abbvie-chip-in-1-billion-to-cure-aging.html</a></p><p>[13] Belluz, J. (2017, April 27). Google is super secretive about its anti-aging research. No one knows why. Retrieved July 22, 2020, from <a href="https://www.vox.com/science-and-health/2017/4/27/15409672/google-calico-secretive-aging-mortality-research">https://www.vox.com/science-and-health/2017/4/27/15409672/google-calico-secretive-aging-mortality-research</a></p><p>[14] Zaleski, A. (2018, August 29). Why Jeff Bezos is backing this Silicon Valley scientist who is working on a cure for aging. Retrieved July 21, 2020, from <a href="https://www.cnbc.com/2018/08/29/jeff-bezos-backs-silicon-valley-scientist-working-on-a-cure-for-aging.html">https://www.cnbc.com/2018/08/29/jeff-bezos-backs-silicon-valley-scientist-working-on-a-cure-for-aging.html</a></p><p>[15] The Longevity Fund. (n.d.). Investing in Human Longevity. Retrieved July 21, 2020, from <a href="https://www.longevity.vc/">https://www.longevity.vc/</a></p><p>[16] Niccoli T, Partridge L. Ageing as a risk factor for disease. <em>Curr Biol</em>. 2012;22(17):R741-R752. doi:10.1016/j.cub.2012.07.024</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4c724726dee5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Recent Breakthroughs in Research Give Hope in the Quest to Cure Aging]]></title>
            <link>https://medium.com/@jessecoutin/recent-breakthroughs-in-research-give-hope-in-the-quest-to-cure-aging-cc34e26285a0?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/cc34e26285a0</guid>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[lifespan]]></category>
            <category><![CDATA[advocacy]]></category>
            <category><![CDATA[research]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Fri, 14 Aug 2020 01:30:09 GMT</pubDate>
            <atom:updated>2021-09-03T20:17:14.918Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vgBm0ENFS_0T6Rsr28sHVw.jpeg" /><figcaption>Photo of gel electrophoresis by <a href="https://unsplash.com/@nci">NCI</a> on Unsplash</figcaption></figure><h4><strong>Potential Treatments for Aging are in the Works</strong></h4><p>Recent research suggests that aging is treatable and potentially reversible. The identification of the nine inter-related hallmarks of aging in the 2013 review paper “The Hallmarks of Aging” in the journal Cell, brought the notion that aging could be addressed therapeutically into the mainstream and spawned a flurry of research into the aging process. At the time of this writing, the 2013 paper, “The Hallmarks of Aging,” has been cited over six thousand times. Additionally, the advent of new technologies for genetic programming, such as CRISPR-Cas9 in 2013 [10], discoveries in the field of stem cells, most notably the discovery of Yamanaka factors, to generate Induced Pluripotent Stem Cells (IPSCs) from somatic cells by Shinya Yamanaka in 2006 [1], and technological advancements in the field of proteomics such as more precise and efficient microscopy, histology, and mass spectrometry [2], have given scientists the tools necessary to attempt to target the hallmarks of aging and repair them. Advances such as these have led to several anti-aging breakthroughs in recent years, with a central theme being that targeting just one hallmark of aging usually confers benefits to multiple other hallmarks.</p><h4>Recent Successes in Research:</h4><p>· <strong>Using Yamanaka Factors to Reprogram Cells to a Younger State:</strong> One of the greatest breakthroughs involved the use of Yamanaka factors, four master genes, Oct4, Sox2, Klf4, and c-Myc (<em>OSKM</em>), which can be induced and expressed in somatic cells to create induced pluripotent stem cells (iPSCs). IPSCs are very similar to embryonic stem cells, in that they do not have a cellular identity and have the capability of differentiating into any type of cell (pluripotency). In 2016, researchers at the Salk Institute demonstrated that “partial reprogramming” using a short-term cyclic Yamanaka factor protocol to briefly activate and then deactivate Yamanaka factors returned prematurely-aged cells and tissues to an epigenetically and physiologically younger state, without turning the cells all the way into stem cells. When this was performed in vivo (live specimen) in prematurely aged (progeroid) mice, the researchers found that it rejuvenated the mice, extending lifespan by 25% without leading to loss of cellular identity or tumor formation. This translated to improvement in common aging phenotypes in the skin, spleen, kidneys, muscle, and stomach tissues. Intriguingly, this research is especially significant because it showed that multiple aging hallmarks — epigenetic alterations, cellular senescence, and stem-cell depletion — were improved with this one therapy [3].</p><p>The work at Salk has opened the door to the future possibility of using Yamanaka factors to epigenetically reprogram humans to a younger state. While this has exciting implications for extending life and health, more research is needed. The focus currently is on using three of the four Yamanaka factors, Oct4, Sox2, and Klf4 (OSK) to restore vision by reprogramming aged or damaged eyes to a younger state, and this has now been done successfully in old mice and mice with glaucoma [4]. The next step will be testing the Yamanaka factors (OSK) on the entire body of aged mice in vivo, and if successful, moving to clinical trials in humans.</p><p>· <strong>NAD+ supplementation</strong>: NAD+ is a molecule which is essential for cellular respiration, yet levels of NAD+ decline with age, apparently because NAD+ is actively destroyed by the enzyme CD38 [5]. Addressing the issue of CD38 destroying NAD+ requires further research, so instead, boosting NAD+ levels is currently being investigated as a treatment. NAD+ precursor supplements are being marketed as anti-aging therapies, although research in mice has demonstrated only modest health and lifespan improvements with these supplements so far. Nevertheless, NAD+ precursor supplements, such as Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR) have been shown to increase NAD+ levels in the tissues of aged mice [6], and higher NAD+ levels are beneficial in light of several of the hallmarks of aging. Higher NAD+ levels stabilize telomeres by activating sirtuins [7], and improve mitochondrial and stem cell function [8]. These cellular changes are reflected in increased performance of aged mice during endurance exercise and better vascular functioning and vascular regeneration [9]. A project to elucidate the long-term effects of NMN supplementation on mice is being led by Dr. David Sinclair, a professor at Harvard whose specialty is aging and genetics, and is set to conclude in late 2020.</p><p>· <strong>Thymus Regeneration: </strong>The thymus is an organ of the immune system, located between the lungs, and it is responsible for producing T-cells, which are an integral part of the adaptive immune system. As we age, in a process called thymic involution, the thymus gland shrinks and is eventually replaced entirely by fat at the age of 65. Immunosenescence is an effect of thymic involution, and hormonal therapies to regenerate the thymus have had promising beneficial results in terms of improved immune functioning in the elderly. A thymus regeneration study, published in 2019, was conducted at UCLA by Steve Horvath, a Professor, geneticist, and bio-statistician, who developed an epigenetic clock (Horvath clock) which can be used to determine biological age, as opposed to chronological age. The study, <em>Thymus Regeneration, Immunorestoration, and Insulin Mitigation (TRIIM)</em>, involved 51–65 year old men who were administered a drug cocktail of 3 drugs: recombinant human growth hormone (rHGH) to restore HGH levels, metformin, a known anti-aging drug that functions as a dietary restriction and exercise mimetic, and dehydroepiandrosterone (DHEA), a synthetic version of the natural hormone necessary for production of testosterone and estrogen, levels of which drop with age. After 1 year of TRIIM, epigenetic age was reversed by 2.5 years on average, and observed effects included thymus regrowth, decreases in inflammation, and improved immune health [10].</p><p>· <strong>Hypothalamus stem cell rejuvenation: </strong>In 2017, researchers discovered that the hypothalamus, a region of the brain responsible for the release of hormones, appears to regulate the speed of aging via the release of exosomal microRNAs, which diminish with age due to depletion of hypothalamic stem cells. When stem cells were injected into the hypothalamus in mice, aging was slowed and lifespan was increased by about 10% [11].</p><p>· <strong>Senolytics: </strong>Senolytics, small molecules which aid the removal of senescent cells, are a proposed treatment for the accumulation of senescent cells with age. Senescent cells are dysfunctional, and are one of the causes of inflammaging, the increased smoldering background inflammation with age, which is linked to decreased immune functioning, increased cancer-risk, and various other age-related diseases such as frailty, atherosclerosis and Alzheimer’s [12]. A study published in 2018 in the journal Nature found that when the senolytics Dasatinib plus Quercetin (D+Q) were administered to aged mice, there was a decrease in inflammation, improvement in physical activity, and an increase in life-span by 36% [13]. Senolytic therapies such as D+Q have now moved into clinical trials for a variety of diseases, and preliminary results show decreased numbers of senescent cells in humans, and that senolytics appear have minimal side-effects [14].</p><h4><strong>Conclusion</strong></h4><p>This paper covers several of the major breakthroughs in aging research in recent years, and each proves that aging is a modifiable process that can be adjusted to confer health benefits and extend lifespan. With more research and clinical trials, we could soon see these potential therapies in actual practice by medical professionals. More funding is definitely needed to accelerate such research.</p><p>Interested in how much funding is available for aging research, where it comes from, and how we can advocate for more? Read my final article in this series, <a href="https://medium.com/@jessecoutin/aging-research-where-is-the-funding-4c724726dee5">“Aging Research; Where is the funding?”</a></p><p>Missed my first two articles, find them here: <a href="https://medium.com/@jessecoutin/where-is-the-operation-warp-speed-for-aging-2e3b21c606f4">“Where is the ‘Operation Warp Speed’ for Aging?”</a> and here: <a href="https://medium.com/@jessecoutin/what-causes-aging-how-much-have-we-learned-in-recent-years-93b85e6a594a">“What Causes Aging? How Much Have we Learned in Recent Years?”</a></p><h4><strong>References:</strong></h4><p>[1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. <em>Cell</em>. 2006;126(4):663–676. doi:10.1016/j.cell.2006.07.024</p><p>[2] Yates J. R., 3rd (2019). Recent technical advances in proteomics. <em>F1000Research</em>, <em>8</em>, F1000 Faculty Rev-351. <a href="https://doi.org/10.12688/f1000research.16987.1">https://doi.org/10.12688/f1000research.16987.1</a></p><p>[3] Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., Li, M., Lam, D., Kurita, M., Beyret, E., Araoka, T., Vazquez-Ferrer, E., Donoso, D., Roman, J. L., Xu, J., Rodriguez Esteban, C., Nuñez, G., Nuñez Delicado, E., Campistol, J. M., Guillen, I., … Izpisua Belmonte, J. C. (2016). In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. <em>Cell</em>, <em>167</em>(7), 1719–1733.e12. <a href="https://doi.org/10.1016/j.cell.2016.11.052">https://doi.org/10.1016/j.cell.2016.11.052</a></p><p>[4] Lu, Y., Krishnan, A., Brommer, B., Tian, X., Meer, M., Vera, D. L., … &amp; Yang, J. H. (2019). Reversal of ageing-and injury-induced vision loss by Tet-dependent epigenetic reprogramming. <em>bioRxiv</em>, 710210.</p><p>[5] Schultz, M. B., &amp; Sinclair, D. A. (2016). Why NAD(+) Declines during Aging: It’s Destroyed. <em>Cell metabolism</em>, <em>23</em>(6), 965–966. <a href="https://doi.org/10.1016/j.cmet.2016.05.022">https://doi.org/10.1016/j.cmet.2016.05.022</a></p><p>[6] Yoshino, J., Baur, J. A., &amp; Imai, S. I. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. <em>Cell metabolism</em>, <em>27</em>(3), 513–528. <a href="https://doi.org/10.1016/j.cmet.2017.11.002">https://doi.org/10.1016/j.cmet.2017.11.002</a></p><p>[7] Amano, H., Chaudhury, A., Rodriguez-Aguayo, C., Lu, L., Akhanov, V., Catic, A., Popov, Y. V., Verdin, E., Johnson, H., Stossi, F., Sinclair, D. A., Nakamaru-Ogiso, E., Lopez-Berestein, G., Chang, J. T., Neilson, J. R., Meeker, A., Finegold, M., Baur, J. A., &amp; Sahin, E. (2019). Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. <em>Cell metabolism</em>, <em>29</em>(6), 1274–1290.e9. <a href="https://doi.org/10.1016/j.cmet.2019.03.001">https://doi.org/10.1016/j.cmet.2019.03.001</a></p><p>[8] Zhang H, Ryu D, Wu Y, et al. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. <em>Science</em>. 2016;352(6292):1436–1443. doi:10.1126/science.aaf2693</p><p>[9] Tarantini, S., Valcarcel-Ares, M. N., Toth, P., Yabluchanskiy, A., Tucsek, Z., Kiss, T., Hertelendy, P., Kinter, M., Ballabh, P., Süle, Z., Farkas, E., Baur, J. A., Sinclair, D. A., Csiszar, A., &amp; Ungvari, Z. (2019). Nicotinamide mononucleotide (NMN) supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses and improves cognitive function in aged mice. <em>Redox biology</em>, <em>24</em>, 101192. <a href="https://doi.org/10.1016/j.redox.2019.101192">https://doi.org/10.1016/j.redox.2019.101192</a></p><p>[10] Fahy, GM, Brooke, RT, Watson, JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. <em>Aging Cell</em>. 2019; 18:e13028. <a href="https://doi.org/10.1111/acel.13028">https://doi.org/10.1111/acel.13028</a></p><p>[11] Zhang, Y., Kim, M. S., Jia, B., Yan, J., Zuniga-Hertz, J. P., Han, C., &amp; Cai, D. (2017). Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. <em>Nature</em>, <em>548</em>(7665), 52–57. <a href="https://doi.org/10.1038/nature23282">https://doi.org/10.1038/nature23282</a></p><p>[12] Rezuș E, Cardoneanu A, Burlui A, et al. The Link Between Inflammaging and Degenerative Joint Diseases. <em>Int J Mol Sci</em>. 2019;20(3):614. Published 2019 Jan 31. doi:10.3390/ijms20030614</p><p>[13] Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., Onken, J. L., Johnson, K. O., Verzosa, G. C., Langhi, L., Weigl, M., Giorgadze, N., LeBrasseur, N. K., Miller, J. D., Jurk, D., Singh, R. J., … Kirkland, J. L. (2018). Senolytics improve physical function and increase lifespan in old age. <em>Nature medicine</em>, <em>24</em>(8), 1246–1256. <a href="https://doi.org/10.1038/s41591-018-0092-9">https://doi.org/10.1038/s41591-018-0092-9</a></p><p>[14] Hickson, L. J., Langhi Prata, L., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., Kellogg, T. A., Khosla, S., Koerber, D. M., Lagnado, A. B., Lawson, D. K., LeBrasseur, N. K., Lerman, L. O., McDonald, K. M., McKenzie, T. J., Passos, J. F., … Kirkland, J. L. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. <em>EBioMedicine</em>, <em>47</em>, 446–456. <a href="https://doi.org/10.1016/j.ebiom.2019.08.069">https://doi.org/10.1016/j.ebiom.2019.08.069</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cc34e26285a0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What causes Aging? How Much Have we Learned in Recent Years?]]></title>
            <link>https://medium.com/@jessecoutin/what-causes-aging-how-much-have-we-learned-in-recent-years-93b85e6a594a?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/93b85e6a594a</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[lifespan]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Fri, 14 Aug 2020 01:22:56 GMT</pubDate>
            <atom:updated>2020-08-14T02:59:59.842Z</atom:updated>
            <content:encoded><![CDATA[<h3>What Causes Aging? How Much Have We Learned in Recent Years?</h3><p>Surprisingly, the biology of aging is becoming clear.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/782/1*SY290JziXcfLi2Ai-jV9VQ.png" /><figcaption>From “The Hallmarks of Aging” in the journal <em>Cell, 2013</em></figcaption></figure><p><strong>Evidence That There are Molecular Mechanisms of Aging</strong></p><p>Research at universities and in the private sector has made significant in-roads into the causes of aging at the cellular and molecular level. Changes at this level occur in our cells as we get older and seem to have a large impact on the body as a whole, contributing to or perhaps directly causing the age-related diseases that are house-hold names. These changes cumulatively described as biological aging come from two sources: accumulation of damage and programmed aging. Some examples of accumulation of damage are metabolic waste accumulating with age causing mitochondrial dysfunction and U.V. radiation causing damage to DNA, some of which goes unrepaired. Programmed aging is exemplified by biological clocks, such as telomeres, the protective caps at the end of chromosomes, which get shorter with each cellular division, eventually leading to senescence (the inability of the cell to replicate) after a certain number of divisions known as the Hayflick limit [1]. A more recently discovered biological clock, called the Horvath clock, consists of epigenetic modifications which turn on or off genes that influence the rate of aging [2]. Together, aging from unrepaired damage and programmed aging cause a complex variety of dysfunctions at the cellular level known as the nine hallmarks of aging [1], and it is thought that these hallmarks collectively lead to the systemic changes and dysfunctions that we recognize as aging.</p><p><strong>The Nine Hallmarks of Aging are:</strong></p><p>· <strong>Genomic instability</strong>: Damage to the nuclear DNA and mitochondrial DNA, as well as to the nuclear lamina occurs due to extrinsic factors, such as viruses, UV damage, and chemicals, and from intrinsic factors, such as DNA replication errors, reactive oxygen species (ROS), and spontaneous hydrolysis. Although there are built-in DNA repair mechanisms, genomic damage accumulates with age, and can cause “premature aging” if it accumulates quickly [1].</p><p>· <strong>Telomere attrition</strong>: Telomeres are sections of repeated DNA sequences that serve as protective caps at the ends of chromosomes. Telomeres get shorter with each cellular division, eventually leading to a loss of replicative capacity, aka the Hayflick limit, at which point cells enter either senescence (a state of halted cellular division) or apoptosis (programmed cell death). Telomere shortening is correlated with physiological aging, and activating an enzyme called telomerase, which lengthens telomeres, has been shown to increase median lifespan, although not extending maximum lifespan [3]. Unfortunately, DNA damage accumulates to a greater degree in telomeres than other DNA because of the presence of complexes called shelterins. Shelterins have the essential function of forming T-loops at the ends of chromosomes, which protect telomeres by preventing them from being recognized as DNA damage by DNA Polymerase. However, this also has the negative effect of making it impossible for DNA polymerase to repair telomeric damage [1]. Therefore, addressing this hallmark may require both extending telomeres and developing a way to repair DNA damage in telomeres.</p><p>· <strong>Epigenetic alterations</strong>: Epigenetics are modifications that do not change the DNA sequence, but instead turn genes “on” and “off”. There are several epigenetic mechanisms potentially at work during the aging process, such as DNA methylation, histone modifications, and chromatin remodeling. Reversing these epigenetic changes appears to ameliorate some of the effects of aging and even extend life-span in mice. The role of epigenetics in aging is exemplified by the epigenetic enzyme SIRT6, which extends longevity in mice when activated [1]. Epigenetic aging clocks, such as the Horvath clock have been proposed as biomarkers of aging progression, and have been used to determine the effectiveness of anti-aging interventions [2].</p><p>· <strong>Loss of proteostasis</strong>: Proteostasis refers to protein homeostasis, which is the maintenance of stable functional proteins. During aging, proteostasis diminishes and the mechanisms that prevent or repair misfolded proteins, as well as those that remove misfolded proteins (proteolytics) become impaired. Loss of proteostasis causes aggregates of misfolded proteins, which are implicated in Alzheimer’s, Parkinson’s and cataracts [1].</p><p>· <strong>Deregulated nutrient sensing</strong>: Decreased nutrient sensing occurs with increased physiological aging. This may be an adaptive mechanism by cells to reduce metabolism, thereby reducing cellular damage and extending lifespan as we age. Although decreased nutrient signaling can extend lifespan, it can also be lethal to cells at very low levels, which can aggravate aging. Thus, a balance is needed to extend healthy lifespan. There are four nutrient sensing pathways: Insulin and IGF-1 signaling (IIS), mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPk), and sirtuins. The IIS and mTOR pathways signal nutrient abundance, so downregulating them extends lifespan by decreasing cell growth and anabolic metabolism. Conversely, the AMPk and sirtuin pathways signal nutrient scarcity, so their upregulation extends lifespan by decreasing nutrient sensing, thereby mimicking dietary restriction. There are side-effects to upregulating and deregulating some of these nutrient signaling pathways, such as impaired wound healing, insulin resistance, cataract formation, and testicular degeneration when the mTOR pathway is downregulated by rapamycin administration [1]. Therefore we must proceed cautiously when making adjustments to nutrient sensing.</p><p>· <strong>Mitochondrial dysfunction</strong>: Mitochondrial dysfunction refers to mitochondrial degeneration and reduced mitochondrial bioenergetics efficiency. Mitochondrial biogenesis, meaning the increase in the mass of mitochondria, decreases with aging, and damaged mitochondria persist because the ability to remove damaged mitochondria also diminishes with aging. High levels of reactive oxygen species (ROS) can cause damage to mitochondria. Repairing or replacing dysfunctional mitochondria should be beneficial to health span, since we know that mitochondrial dysfunction accelerates aging in mammals [1].</p><p>· <strong>Cellular senescence</strong>: Cellular senescence refers to cells which have entered a state of arrested growth in response to cellular damage. In other words, senescent cells lose functionality and no longer undergo cellular division. Cells become senescent due to telomere shortening, DNA damage, and activation of the <em>INK4a/ARF</em> locus. Senescent cells cause increases in inflammation, which can aggravate aging. Since senescent cells accumulate with age, addressing this hallmark may require preventing the damage that causes senescence as well as improving the body’s capacity to efficiently remove senescent cells. In addition, progenitor cells will need to be able to repopulate tissues with new cells to replace the removed senescent cells [1].</p><p>· <strong>Stem-cell exhaustion</strong>: Stem-cell exhaustion refers to stem cells and progenitor cells accumulating damage over time, and eventually becoming depleted with age. Stem cells and progenitor cells are necessary to maintain functionality of our organs by replacing and repairing damaged cells [1]. Improving stem cell function and replacing depleted stem cells is thus a very promising area of research aimed at improving the regenerative capacity of the body.</p><p>· <strong>Altered intercellular communication</strong>: Aging causes changes in cell-cell signaling at all levels. Neuronal and hormonal signaling become deregulated, resulting in increased inflammation (inflammaging), decreased immune function (immunosenescence), and changes in the extracellular environment. It may be possible to reduce some of the effects of aging by improving cell communication with blood-borne factors and anti-inflammatory agents [1].</p><h3>Conclusion</h3><p>Scientists and aging researchers have garnered a great deal of knowledge regarding the biological mechanisms of aging in recent years. However, there is still much to learn about the drivers of aging, especially in regards to how the nine hallmarks of aging affect one another. The more we know about the biology of aging, the easier it will be to develop therapies that target the specific causes of aging. With the knowledge we have, scientists at universities and in the private sector are already at work developing potential treatments for aging.</p><p>Interested in learning about research on potential treatments for aging? Find my next article <a href="https://medium.com/@jessecoutin/recent-breakthroughs-in-research-give-hope-in-the-quest-to-cure-aging-cc34e26285a0">here</a>. Missed my first article on why aging should be a priority? Find that <a href="https://medium.com/@jessecoutin/where-is-the-operation-warp-speed-for-aging-2e3b21c606f4">here</a>.</p><p>References:</p><p>[1] López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., &amp; Kroemer, G. (2013). The hallmarks of aging. <em>Cell</em>, <em>153</em>(6), 1194–1217. <a href="https://doi.org/10.1016/j.cell.2013.05.039">https://doi.org/10.1016/j.cell.2013.05.039</a></p><p>[2] Raj, K., &amp; Horvath, S. (2020). Current perspectives on the cellular and molecular features of epigenetic ageing. <em>Experimental Biology and Medicine</em>. <a href="https://doi.org/10.1177/1535370220918329">https://doi.org/10.1177/1535370220918329</a></p><p>[3] Bernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., &amp; Blasco, M. A. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. <em>EMBO molecular medicine</em>, <em>4</em>(8), 691–704. <a href="https://doi.org/10.1002/emmm.201200245">https://doi.org/10.1002/emmm.201200245</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=93b85e6a594a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Where is the ‘Operation Warp Speed’ for Aging?]]></title>
            <link>https://medium.com/@jessecoutin/where-is-the-operation-warp-speed-for-aging-2e3b21c606f4?source=rss-a7ceb4114e6f------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e3b21c606f4</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[advocacy]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Jesse Coutin]]></dc:creator>
            <pubDate>Fri, 14 Aug 2020 01:11:05 GMT</pubDate>
            <atom:updated>2020-09-09T00:30:38.844Z</atom:updated>
            <content:encoded><![CDATA[<h3>Aging Research Should be a Priority</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/486/1*KpOiIokNBym0WHEAB-3A8Q.png" /><figcaption>Yes, I know it’s a meme. It should be real.</figcaption></figure><p>As the 2020 election draws near, we in the U.S. are reminded of the issues that are most important to us. Perhaps for you, like most Americans, solutions to mitigate the COVID-19 pandemic and affordable access to quality healthcare are chief among these issues. Perhaps you hope that the U.S. government will be able to accelerate COVID-19 vaccine development with its $10 billion program ‘Operation Warp Speed’. Maybe it will. However, if these are your primary concerns, then getting funding for aging research should be a top priority, especially if you are an older adult, or if you have friends or family that are elderly. As you are probably aware, the COVID-19 pandemic disproportionately affects older adults. In fact, 80% of hospitalizations from Covid-19 are adults older than 65 years of age [1]. Older COVID-19 patients have a death-rate far greater than the general population, and this death rate increases exponentially with advancing age [1,2,3,4].</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*J-UxOPWrXcWquJlRtO462w.png" /><figcaption>Chart from WHO, showing exponential increase in COVID-10 mortality with age.</figcaption></figure><p>Although the novel coronavirus may be your top concern at this time, I suggest you turn your attention to an underlying disease process ubiquitous in humans that receives far less attention: aging. If we could treat aging itself, the effects of this pandemic would certainly be muted.</p><blockquote>I suggest you turn your attention to an underlying disease process ubiquitous in humans that receives far less attention: aging.</blockquote><p>Sure we want quality healthcare and vaccines for Covid-19, but why is it that in the 21st century, the elderly in the developed world are still at the greatest risk of mortality and morbidity not just from COVID, but from most diseases, including neurodegenerative diseases, cardiovascular illnesses, and cancer? [5] The reason seems fairly obvious. It is because aging itself is not being treated as a disease, and therefore research to develop aging therapies is not getting the attention and funding that it deserves.</p><p>The reason that our aging populations are particularly vulnerable to disease is because biological aging causes chronic aberrant and deleterious systemic processes, such as inflammaging (chronic inflammation with increased age) and immunosenescence (weakening of immune function with increased age), which are implicated in the disproportionate COVID-19 mortality rates in the elderly [1]. Fighting aging is an issue that is conspicuously absent from presidential platforms and the public theater, yet it is critically urgent that we come together as a species to advocate for funding to address the greatest risk factor for illness and death: aging itself.</p><h4><strong>Aging is a Disease and There is Evidence That it May Be Treatable</strong></h4><p>To an outside observer, aging has a fairly obvious phenotype: Hair graying and thinning, and skin wrinkling beginning in our third and fourth decades of life, tooth decay and the need for glasses in our fourth, fifth, and sixth decades of life, and age spots, loss of muscle tone and strength, diminished height, and aches and pains in the decades after that. We all know that these unwanted changes occur as we age, and yet we do not talk about aging as though it is a disease.</p><p>To the medical professional, aging is more than these readily observable traits. From a medical perspective, aging is the greatest risk factor for diseases that affect every organ and body system. With advancing age, the risk increases dramatically for: cardio-vascular disease which can lead to strokes, heart attacks, and chronic obstructive pulmonary disease (COPD), infections and aberrant and ineffective immune responses [4], eye diseases such as macular degeneration, glaucoma, and cataracts, cancer, kidney disease, liver disease, Alzheimer’s disease, dementia, and cognitive decline, frailty (muscle atrophy and osteoporosis), inflammatory syndromes such as gout and arthritis, and metabolic syndromes such as diabetes [6, 7].</p><p>The current medical approach is to treat each age-related disease as it occurs, and to prevent them as much as possible with a healthy life-style and exercise. While this has some benefit, it is an approach which is ultimately doomed to failure, as the most significant cause of each of these diseases, aging, is still going untreated. If you walk into a doctor’s office at the age of 65 and complain that you are old with a laundry list of age-related problems, the doctor may be able to help with some of your symptoms, but will have nothing to offer you to treat their underlying cause.</p><p>Appropriate funding and attention should be given to research in gerontology, the study of aging, but instead the issue is being sidelined while it continues to wreak havoc on humanity. Aging should be treated like any other disease, since the biological underpinnings of aging are becoming better understood every day and potential therapies are being investigated, albeit slowly.</p><p>Interested in the biological causes of aging? Read my follow-up article, <a href="https://medium.com/@jessecoutin/what-causes-aging-how-much-have-we-learned-in-recent-years-93b85e6a594a">“What causes aging? How Much Have we Learned in Recent Years?”</a></p><p><strong>References:</strong></p><p>[1] Mueller, A. L., McNamara, M. S., &amp; Sinclair, D. A. (2020). Why does COVID-19 disproportionately affect older people?. <em>Aging</em>, <em>12</em>(10), 9959–9981. <a href="https://doi.org/10.18632/aging.103344">https://doi.org/10.18632/aging.103344</a></p><p>[2] Roser, M., Ritchie, H., Ortiz-Ospina, E., and Hasell, J. (2020) Coronavirus Pandemic (COVID-19). <em>Published online at OurWorldInData.org.</em> https://ourworldindata.org/coronavirus</p><p>[3] Onder G, Rezza G, Brusaferro S. (2020) Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. <em>JAMA</em>. doi:10.1001/jama.2020.4683.</p><p>[4] The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Chinese CDC Weekly. <a href="https://cdn.onb.it/2020/03/COVID-19.pdf.pdf">https://cdn.onb.it/2020/03/COVID-19.pdf.pdf</a>.</p><p>[5] Niccoli T, Partridge L. Ageing as a risk factor for disease. <em>Curr Biol</em>. 2012;22(17):R741-R752. doi:10.1016/j.cub.2012.07.024</p><p>[6] Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., Monti, D., Capri, M., &amp; Salvioli, S. (2018). The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. <em>Frontiers in medicine</em>, <em>5</em>, 61. <a href="https://doi.org/10.3389/fmed.2018.00061">https://doi.org/10.3389/fmed.2018.00061</a></p><p>[7] López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., &amp; Kroemer, G. (2013). The hallmarks of aging. <em>Cell</em>, <em>153</em>(6), 1194–1217. <a href="https://doi.org/10.1016/j.cell.2013.05.039">https://doi.org/10.1016/j.cell.2013.05.039</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e3b21c606f4" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>